TOVX on NYSE

Theriva Biologics, Inc.

We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerTOVX on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRockville, Maryland1
  • Incorporated inNV2
  • Business address9605 Medical Center Drive, Suite 270, Rockville, Md 208502
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L. (“VCN”, formerly named VCN Biosciences, S.L.), in March 2022, as described in more detail below (the “Acquisition”), we transitioned our strategic focus to oncology through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase. VCN - 01 …3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$24.1M in 2025+54% since 2019
-$30.0M-$20.0M-$10.0M02019: -$15.7M-$15.7M20192020: -$10.2M-$10.2M2020−35%2021: -$14.3M-$14.3M2021+40%2022: -$21.6M-$21.6M2022+51%2023: -$21.4M-$21.4M2023−1%2024: -$26.3M-$26.3M2024+23%2025: -$24.1M-$24.1M2025−9%
Net income45679-$23.7M in 2025+55% since 2019
-$30.0M-$20.0M-$10.0M02019: -$15.3M-$15.3M20192020: -$10.0M-$10.0M2020−34%2021: -$14.3M-$14.3M2021+42%2022: -$19.7M-$19.7M2022+38%2023: -$18.3M-$18.3M2023−7%2024: -$25.7M-$25.7M2024+40%2025: -$23.7M-$23.7M2025−7%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
General and administrative$15.4M$7.4M
Research and development$8.6M$12.0M
In-process research and development impairment$0$1.3M
Goodwill impairment$5.6M
Total Operating Costs and Expenses$24.1M$26.3M
Loss from Operations-$24.1M-$26.3M
Foreign currency exchange gain (loss)$25.0K-$4.0K
Interest income$287.0K$697.0K
Total Other Income$312.0K$693.0K
Net Loss before income taxes-$23.7M-$25.7M
Net Loss-$23.7M-$25.7M
Less deemed dividend from warrant inducement-$1.5M
Net Loss Attributable to Common Stockholders-$25.2M-$25.7M
Net Loss Per Share - Basic (in dollars per share)-$2.08-$19.03
Net Loss Per Share - Dilutive (in dollars per share)-$2.08-$19.03
Weighted average number of shares outstanding during the period - Basic (in shares)12.1M shares1.3M shares
Weighted average number of shares outstanding during the period - Dilutive (in shares)12.1M shares1.3M shares
Gain (loss) on foreign currency translation$1.9M-$1.2M
Total comprehensive loss-$21.8M-$26.9M

Compare Theriva Biologics, Inc. with another company

Leadership

Who has led Theriva Biologics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael F. Manion2006
  2. Steve H. Kanzer2006–2008
  3. Nicholas Stergis2008
  4. Lyman Max Lyon Jr.2009
  5. James S. Kuo2010–2011
  6. Steven A. Shallcross2017–now

Chair

  1. Steve H. Kanzer2009
  2. James S. Kuo2010–2011

President

  1. Michael F. Manion2006
  2. Charles Bisgaier Phd.2007
  3. Lyman Max Lyon Jr.2009
  4. James S. Kuo2010–2011

Chief financial officer

  1. Charles Evan Ballantyne2012–2015
  2. Steven A. Shallcross2015–now

Chief operating officer

  1. Francis Tufaro2022
2010201520202025
Board members and other officers (15)

Former names

  • Synthetic Biologics, Inc.Mar 12, 2012 to Oct 12, 20222
  • ADEONA PHARMACEUTICALS, INC.Aug 26, 2008 to Feb 17, 20122
  • PIPEX PHARMACEUTICALS, INC.Dec 14, 2006 to Oct 16, 20082
  • SHEFFIELD PHARMACEUTICALS INCSep 10, 1997 to Dec 8, 20062
  • SHEFFIELD MEDICAL TECHNOLOGIES INCMay 7, 1996 to May 14, 19972

Timeline

  1. Dec 21, 2017New chief executive Steven A. Shallcross becomes CEO12
  2. Mar 3, 2010New chief executive James S. Kuo becomes CEO13
  3. Aug 3, 2009New chief executive Lyman Max Lyon Jr. becomes CEO14
  4. Jul 14, 2008New chief executive Nicholas Stergis becomes CEO15
  5. Nov 13, 2006New chief executive Steve H. Kanzer becomes CEO17
  6. Aug 11, 2006New chief executive Michael F. Manion becomes CEO16

Filings

242 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 103 major events, 29 insider forms, 9 large holders, 3 private raises, 78 other. The latest 20:

  1. Oct 9, 2026PRE 14A EDGAR
  2. Aug 24, 2026S-8 EDGAR
  3. Aug 11, 202610-Q EDGAR
  4. Aug 11, 20268-K EDGAR
  5. Aug 6, 20268-K EDGAR
  6. Aug 4, 20268-K EDGAR
  7. Jul 7, 20268-K EDGAR
  8. Jun 29, 2026ARS EDGAR
  9. Jun 29, 2026DEF 14A EDGAR
  10. Jun 18, 2026PRE 14A EDGAR
  11. Jun 11, 20268-K EDGAR
  12. Jun 5, 20268-K EDGAR
  13. May 5, 202610-Q EDGAR
  14. May 5, 20268-K EDGAR
  15. Apr 30, 2026DEF 14A EDGAR
  16. Apr 20, 2026PRE 14A EDGAR
  17. Apr 17, 20268-K EDGAR
  18. Apr 9, 20268-K EDGAR
  19. Mar 23, 20268-K EDGAR
  20. Mar 16, 2026DEF 14A EDGAR

The 242 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 7, 2023SHALLCROSS STEVEN ACEO and CFOBuy14,000$0.69$9.7KForm 4
Jun 6, 2023SHALLCROSS STEVEN ACEO and CFOBuy26,000$0.63$16.4KForm 4
Feb 10, 2023SHALLCROSS STEVEN ACEO and CFOBuy25,000$1.04$26.0KForm 4
Feb 2, 2023SHALLCROSS STEVEN ACEO and CFOBuy25,000$0.94$23.5KForm 4
Jan 25, 2023SHALLCROSS STEVEN ACEO and CFOBuy25,000$0.87$21.8KForm 4
Jan 20, 2023SHALLCROSS STEVEN ACEO and CFOBuy25,000$0.75$18.8KForm 4
Dec 29, 2022SHALLCROSS STEVEN ACEO and CFOBuy100,000$0.44$44.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 17, 2025Raised $13.1 million in a private offering of securities Form D: 10 investors so far Form D
  2. Jul 29, 2022Raised $3 million in a private offering of equity Form D: 1 investor so far Form D
  3. Mar 10, 2022Raised $1.5 million in a private offering of equity Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 26. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC486,179$121.5K0.0%+293,775
Jane Street Group, LLC331,922$83.0K0.0%+154,888
Geode Capital Management, LLC294,021$73.6K0.0%−156,242
Vanguard Fiduciary Trust Co241,780$60.4K0.0%No change
Ikarian Capital, LLC112,076$28.0K0.0%No change
Northern Trust Corp82,700$20.7K0.0%New
Renaissance Technologies LLC63,710$15.9K0.0%New
UBS Group AG61,053$15.3K0.0%−164,571
XTX Topco Ltd53,868$13.5K0.0%−40,752
Ground Swell Capital, LLC35,292$8.8K0.0%New
Boothbay Fund Management, LLC27,646$6.9K0.0%No change
Susquehanna International Group, Llp24,064$6.0K0.0%New
Morgan Stanley20,299$5.1K0.0%−3,303
Two Sigma Securities, LLC19,748$4.9K0.0%−85,493
Two Sigma Investments, LP15,456$3.9K0.0%+15
Schwarz Dygos Wheeler Investment Advisors LLC15,000$3.8K0.0%No change
BlackRock, Inc.7,504$1.9K0.0%No change
Osaic Holdings, Inc.441$1100.0%+433
SBI Securities Co., Ltd.358$900.0%+227
Northwestern Mutual Wealth Management Co100$250.0%New
Virtu Financial LLC87,138$220.0%−166,080
IFP Advisors, Inc11$30.0%No change
Barclays PLC3$10.0%New
NFSG Corp5$10.0%No change
Danske Bank A/s1$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43